WO2026056858 - ANTI-ULCERATIVE COLITIS PHARMACEUTICAL COMPOSITION CONTAINING ICARITIN
National phase entry is expected:
Publication Number
WO/2026/056858
Publication Date
19.03.2026
International Application No.
PCT/CN2025/120080
International Filing Date
09.09.2025
Title **
[English]
ANTI-ULCERATIVE COLITIS PHARMACEUTICAL COMPOSITION CONTAINING ICARITIN
[French]
COMPOSITION PHARMACEUTIQUE ANTI-COLITE ULCÉREUSE CONTENANT DE L'ICARITINE
[Chinese]
一种含有淫羊藿苷元的抗溃疡性结肠炎药物组合物
Applicants **
LUNAN PHARMACEUTICAL GROUP CORPORATION
Inventors
ZHANG, Guimin
YAO, Jingchun
LI, Shirong
JIANG, Mingmin
FENG, Qun
GAO, Lei
WANG, Huiping
Priority Data
202411261219.7
10.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1576 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 2001 | |
| South Korea | Filing, Examination, Granting | 1805 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,698
Contact Us
Abstract[English]
Disclosed are a pharmaceutical composition for preventing and treating ulcerative colitis, a preparation method therefor, and use thereof. The pharmaceutical composition comprises icaritin or a pharmaceutically acceptable salt thereof and N-(3-chlorophenyl)-1-(3-hydroxybenzoyl)piperidine-4-carboxamide or a pharmaceutically acceptable salt thereof, and the weight ratio of icaritin to N-(3-chlorophenyl)-1-(3-hydroxybenzoyl)piperidine-4-carboxamide is 0.1-3.0:1. Icaritin or the pharmaceutically acceptable salt thereof and N-(3-chlorophenyl)-1-(3-hydroxybenzoyl)piperidine-4-carboxamide or the pharmaceutically acceptable salt thereof in the pharmaceutical composition exhibit a significant synergistic effect in preventing or treating ulcerative colitis, resulting in a notable therapeutic effect on ulcerative colitis.[French]
L'invention concerne une composition pharmaceutique pour la prévention et le traitement de la rectocolite hémorragique, son procédé de préparation et son utilisation. La composition pharmaceutique comprend de l'icaritine ou un sel pharmaceutiquement acceptable de celle-ci et du N- (3-chlorophényl)-1-(3-hydroxybenzoyl) pipéridine-4-carboxamide ou un sel pharmaceutiquement acceptable de celle-ci, et le rapport pondéral de l'icaritine au N-(3-chlorophényl)-1-(3-hydroxybenzoyl)pipéridine-4-carboxamide est de 0,1 à 3,0 : 1. L'icaritine ou son sel pharmaceutiquement acceptable et le N-(3-chlorophényl)-1-(3-hydroxybenzoyl)pipéridine-4-carboxamide ou son sel pharmaceutiquement acceptable dans la composition pharmaceutique présentent un effet synergique significatif dans la prévention ou le traitement de la rectocolite hémorragique, conduisant à un effet thérapeutique notable sur la rectocolite hémorragique.[Chinese]
一种防治溃疡性结肠炎的药物组合物及制备方法和用途。所述药物组合物包含淫羊藿苷元或其药学上可接受的盐和N-(3-氯苯基)-1-(3-羟基苯甲酰基)哌啶-4-甲酰胺或其药学上可接受的盐，所述淫羊藿苷元和所述N-(3-氯苯基)-1-(3-羟基苯甲酰基)哌啶-4-甲酰胺重量比为0.1-3.0:1。所述药物组合物中淫羊藿苷元或其药学上可接受的盐和N-(3-氯苯基)-1-(3-羟基苯甲酰基)哌啶-4-甲酰胺或其药学上可接受的盐在预防或治疗溃疡性结肠炎方面具有显著的协同增效作用，对溃疡性结肠炎治疗效果显著。